BioNexus Gene Lab Corp.
BGLC
$5.30
-$0.12-2.21%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 5.76% | -15.33% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5.76% | -15.33% | |||
| Cost of Revenue | 5.50% | -19.01% | |||
| Gross Profit | 7.13% | 11.09% | |||
| SG&A Expenses | 11.40% | 381.58% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -164.85% | -102.30% | |||
| Total Operating Expenses | 5.83% | -14.88% | |||
| Operating Income | -6.05% | 13.21% | |||
| Income Before Tax | 1.14% | -47.70% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 1.14% | -78.95% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1.14% | -78.95% | |||
| EBIT | -6.05% | 13.21% | |||
| EBITDA | -6.12% | 13.36% | |||
| EPS Basic | 1.12% | -79.00% | |||
| Normalized Basic EPS | -5.29% | -19.98% | |||
| EPS Diluted | 1.12% | -79.00% | |||
| Normalized Diluted EPS | -5.29% | -19.98% | |||
| Average Basic Shares Outstanding | -0.01% | -0.01% | |||
| Average Diluted Shares Outstanding | -0.01% | -0.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||